Several studies have similarly demonstrated that fecal myeloperoxidase is strongly associated with disease activity in patients with IBD, reinforcing its potential as a reliable biomarker for monitoring disease severity [56,70,71]. This evidence concerns the gene MPO and irritable bowel syndrome.